文献速递骨软组织肉瘤与黑色素瘤

开放标签、多中心、随机、II期研究:EpSSG与ITCC评估在儿童及青少年转移性软组织肉瘤化疗中加入贝伐珠单抗(BERNIE研究)

Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study).
PubMed 文献 · Eur J Cancer · 2017-08-23

BERNIE研究随机分配154例转移性横纹肌肉瘤(RMS)或非横纹肌肉瘤软组织肉瘤(NRSTS)儿童及青少年,比较化疗联合或不联合贝伐珠单抗的疗效。主要终点无事件生存(EFS)在两组间无统计学显著改善(分层HR=0.93,95%CI 0.61-1.41,P=0.72)。联合贝伐珠单抗耐受性可,但未显著改善EFS。

要点

  • 转移性RMS/NRSTS患儿化疗联合贝伐珠单抗未显著改善EFS(分层HR=0.93,P=0.72)。
  • RMS亚组EFS的HR=1.24(95%CI 0.73-2.09),NRSTS亚组HR=0.64(95%CI 0.32-1.26)。
  • 客观缓解率化疗组36.0% vs 联合组54.0%,差值18.0%(95%CI 0.6-35.3)。

核心结论

  • 在转移性RMS/NRSTS儿童及青少年中,化疗联合贝伐珠单抗耐受性可,但主要终点EFS未显示统计学显著改善。

研究设计与样本

  • 开放标签、多中心、随机、II期研究,纳入年龄≥6个月至<18岁的转移性RMS或NRSTS患者。
  • 154例患者随机分配至单纯化疗组(n=80)或化疗联合贝伐珠单抗组(n=74)。
  • 治疗方案包括诱导化疗(4周期IVADo+5周期IVA,±贝伐珠单抗)、手术和/或放疗,后续维持化疗(12周期低剂量环磷酰胺+长春瑞滨,±贝伐珠单抗)。
  • 主要终点为经独立影像学审查委员会评估的EFS。

主要发现

  • 中位EFS:单纯化疗组14.9个月(95%CI 10.8-35.9),联合贝伐珠单抗组20.6个月(95%CI 15.2-24.9),分层HR=0.93(95%CI 0.61-1.41,P=0.72)。
  • RMS患者(n=103)EFS的HR=1.24(95%CI 0.73-2.09),NRSTS患者(n=49)HR=0.64(95%CI 0.32-1.26)。
  • 客观缓解率:单纯化疗组36.0%(95%CI 25.2-47.9),联合贝伐珠单抗组54.0%(95%CI 40.9-66.6),差值18.0%(95%CI 0.6-35.3)。
  • 无治疗相关死亡,联合贝伐珠单抗未增加3/4级毒性发生率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We evaluated the role of bevacizumab as part of the multi-modality treatment of children and adolescents with metastatic rhabdomyosarcoma (RMS) or non-rhabdomyosarcoma soft tissue sarcoma (NRSTS). PATIENTS AND METHODS: Eligible patients aged ≥6 months to <18 years were randomised to receive induction chemotherapy (four cycles of IVADo + five cycles of IVA, ±bevacizumab), surgery and/or radiotherapy, followed by maintenance chemotherapy (12 cycles of low-dose cyclophosphamide + vinorelbine, ±bevacizumab). The primary objective was event-free survival (EFS) evaluated by an independent radiological review committee. RESULTS: One hundred and fifty-four patients were randomised to receive chemotherapy alone (n = 80) or with bevacizumab (n = 74). At the data cut-off for the primary efficacy analysis, median EFS was 14.9 months (95% confidence interval [CI]: 10.8-35.9) with chemotherapy and 20.6 months (95% CI: 15.2-24.9) with bevacizumab plus chemotherapy (stratified hazard ratio [HR] = 0.93; 95% CI: 0.61-1.41; P = 0.72). The HR for EFS in patients with RMS (n = 103) was 1.24 (95% CI: 0.73-2.09) versus 0.64 (95% CI: 0.32-1.26) for those with NRSTS (n = 49). Objective response rate was 36.0% (95% CI: 25.2-47.9) with chemotherapy and 54.0% (95% CI: 40.9-66.6) with bevacizumab plus chemotherapy (difference of 18.0%; 95% CI: 0.6-35.3). There were no treatment-related deaths and no increased incidence of grade 3/4 toxicities with bevacizumab. CONCLUSION: The addition of bevacizumab to chemotherapy appeared tolerable in children and adolescents with metastatic RMS/NRSTS, but the primary end-point of EFS did not show statistically significant improvement. TRIAL REGISTRATION: ClinicalTrials.gov, NCT00643565.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Chisholm JC, Merks JHM, Casanova M, et al. Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study). Eur J Cancer. 2017. PMID: 28738258. doi:10.1016/j.ejca.2017.06.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。